Compare EVC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVC | VNDA |
|---|---|---|
| Founded | 1996 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.0M | 387.9M |
| IPO Year | 2000 | 2005 |
| Metric | EVC | VNDA |
|---|---|---|
| Price | $8.76 | $6.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.90 |
| AVG Volume (30 Days) | ★ 3.6M | 1.0M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.35% | N/A |
| EPS Growth | ★ 47.59 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $536,034,000.00 | $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | N/A | $37.40 |
| P/E Ratio | $69.77 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $1.95 | $4.14 |
| 52 Week High | $10.12 | $9.91 |
| Indicator | EVC | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 58.58 | 39.38 |
| Support Level | $2.70 | $5.85 |
| Resistance Level | $10.12 | $6.73 |
| Average True Range (ATR) | 0.73 | 0.24 |
| MACD | -0.19 | 0.01 |
| Stochastic Oscillator | 47.55 | 8.61 |
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.